ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The French drug company Servier will buy Shire’s cancer-drug business for $2.4 billion. Shire’s marketed products for leukemia and pancreatic cancer represent less than 2% of the rare-disease drug company’s sales. Shire also has an experimental treatment for leukemia under review at the U.S. FDA. News of the sale comes about two weeks after Japan’s Takeda Pharmaceutical announced it was considering a bid to acquire Shire.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X